Search the Newsreel

Insmed (INSM) Is Up 34.2% After Sharp Year-Over-Year Net Loss Reduction - Has The Bull Case Changed?

Insmed (INSM) saw its stock rise 34.2% following a significant reduction in its net loss for Q2 2026, narrowing to US$13.24 million from US$321.69 million a year prior. This improvement in financial performance, along with reiterated revenue guidance for its key drugs BRINSUPRI and …

Insmed (NASDAQ:INSM) COO Sells 239,850 Shares

Insmed (NASDAQ:INSM) COO Roger Adsett sold 239,850 shares of the company's stock for approximately $32.0 million, reducing his direct holdings by over 70%. Despite the sale and a slight dip in stock price, Insmed reported better-than-expected quarterly revenue and adjusted loss per share. Analyst …

Insmed Chief Operating Officer Sold Shares Worth Over $31M

Insmed Chief Operating Officer Roger Adsett sold 98,744 shares of common stock at a weighted average price of $133.27 per share, totaling over $31 million. Following this transaction, Adsett directly owns 98,744 shares. This information is based on an SEC Form 4 filing.

Insmed Inc (INSM) posts 33.0% weekly gain with turnover at 2.4x

The biotechnology stock’s 52-week weekly chart shows a sharp advance, but trend confirmation and relative-strength readings remain mixed.

H.C. Wainwright reiterates Buy on Insmed stock, $220 target

H.C. Wainwright has reiterated a Buy rating on Insmed (NASDAQ:INSM) stock with a $220 price target, driven by the strong performance of its drug Brinsupri. Brinsupri's revenue growth exceeded expectations, with the company raising its 2026 revenue guidance for the drug to $1.25 billion …

INSM (INSM) insider notice covers 239,850 shares and prior sales data

An SEC Form 144 filing by INSMED Inc. indicates a potential sale of 239,850 common shares, with an indicated trading date of August 10, 2026, on NASDAQ. The filing also discloses prior sales by Roger Adsett, including 2,370 shares on June 3, 2026, and …

Insmed (NASDAQ:INSM) Price Target Cut to $175.00 by Analysts at JPMorgan Chase & Co.

JPMorgan Chase & Co. has lowered its price target for Insmed (NASDAQ:INSM) to $175.00 from $179.00, while maintaining an "overweight" rating. This adjustment comes despite Insmed exceeding quarterly earnings expectations, reporting a loss of $0.06 per share against a forecasted $0.67 loss and a …

$1000 Invested In Insmed 5 Years Ago Would Be Worth This Much Today

Insmed (NASDAQ: INSM) has significantly outperformed the market over the last five years, with an annualized return of 41.43%. An initial investment of $1000 made five years ago would now be worth $5,573.37. This demonstrates the powerful effect of compounded returns on investment growth.

Insmed Inc (INSM) jumps 33.0% in a heavy-volume week

The biotechnology stock closed at 131.10 USD, with short-term momentum improving even as trend confirmation and relative strength remain weak.

High Growth Tech Stocks in the US to Watch

The U.S. market is experiencing a significant upswing, with a 21% rise over the past year and expected 17% annual earnings growth. This article highlights high-growth tech stocks that align with these positive trends, focusing on companies with strong innovation, financial health, and market …

Pacer Advisors Inc. Has $1.19 Million Holdings in Insmed, Inc. $INSM

Pacer Advisors Inc. significantly reduced its stake in Insmed, Inc. by 53.3% in the first quarter, now holding 7,279 shares valued at $1.19 million. Despite this, other major institutions like Vanguard and State Street increased their holdings, and Insmed reported strong Q2 results, exceeding …

Is Insmed (INSM) Cheap After Q2 Revenue Growth And Raised Guidance?

Insmed (INSM) has seen renewed investor interest after reporting a smaller net loss and raised full-year revenue guidance in its Q2 2026 earnings. The company's stock has shown strong recent gains, despite a year-to-date decline, and is considered undervalued by Simply Wall St's narrative …

Insmed (NASDAQ:INSM) Posts Earnings Results

Insmed (INSM) Stock Cools As BRINSUPRI Surge Recasts Growth Profile

Insmed's stock experienced a slight dip despite reporting a strong biotech quarter driven by the success of BRINSUPRI, which generated $309.2 million in Q2 revenue and has full-year guidance of $1.25 billion to $1.4 billion. The company's overall quarterly revenue reached $425.5 million, significantly …

What Insmed Stock’s Premium Is Actually Buying

Insmed (INSM) stock trades at a significant premium, 25.3 times sales, despite being 37% below its 52-week high, with this premium driven by an optimistic peak-sales estimate of over $14 billion. This estimate relies heavily on the future success of TPIP, a drug still …

Insmed Tops Q2 Earnings Estimates, Stock Soars 34% on Brinsupri Uptake

Insmed Incorporated Stock 12‑Month Price Target Raised to $197.14, Implies 99% Upside

Insmed Incorporated's average 12-month price target has been increased to $197.14, up from $195.95, with forecasts ranging from $140 to $243 per share. This new target suggests a potential upside of approximately 99% from its August 5th closing price. The consensus rating for Insmed …

INSM|Insmed Inc|Price:134.620|Chg%:+3.520

Insmed (NASDAQ: INSM) hits $731M 2026 product revenue as losses narrow

Insmed (NASDAQ: INSM) reported a significant increase in product revenue for Q2 2026, reaching $425.5 million, and a six-month total of $731.5 million, primarily driven by the launch of BRINSUPRI and continued growth of ARIKAYCE. The company's net loss narrowed to $13.2 million for …

Insmed (INSM) Stock Looks Expensive On Sales But Strong On Returns

Insmed (INSM) stock has seen a significant surge over the past three years, yet current valuation metrics present a mixed picture. While the company's price-to-sales ratio suggests overvaluation compared to industry averages and its modeled fair value, the strong performance and anticipated success of …

Insmed (INSM) Soars 33.86% as Brinsupri Drives Fourfold Growth. Here’s What to Watch Next

Insmed (INSM) experienced a significant 33.86% surge in its share price due to a nearly fourfold increase in Q2 revenues, largely driven by its drug Brinsupri. The company's total revenues jumped 296% to $425.5 million, enabling it to slash its net loss by 96%. …

Reporting person for NASDAQ: INSM plans 27,173-share sale after prior trades

Martina Flammer, a reporting person for INSMED Inc. (NASDAQ: INSM), has filed to sell up to 27,173 shares of common stock through Merrill Lynch, with an approximate sale date of August 6, 2026. This planned sale is related to stock plan activity. The filing …

Insmed Inc Stock (INSM) Moved Up by 31.83% on Aug 6: Key Drivers Unveiled

Insmed Inc (INSM) stock surged by 31.83% due to positive clinical trial data and potential acquisition interest. Analysts have revised revenue models with an average price target of $196.74, while technical indicators suggest a sell signal and oversold conditions. The company's significant equity dilution, …

Insmed, Inc. (NASDAQ:INSM) Given Consensus Rating of "Buy" by Brokerages

Insmed, Inc. (NASDAQ:INSM) has received a consensus "Buy" rating from 26 analysts, with an average 12-month price target of $209.35. Despite recent insider selling and shares trading near their 52-week low, the company reported better-than-expected quarterly earnings with revenue up 229.7% year-over-year. Analysts anticipate …

Insmed Catapults Nearly 40%, Leading A Biotech Rally

Insmed (INSM) stock surged 30% after reporting strong second-quarter sales for its new lung disease drug, Brinsupri, exceeding analyst expectations. The company also raised its full-year guidance for the drug's sales, contributing to a broader rally in the biotech sector. This positive performance helped …

FMR LLC discloses 7.4% Insmed Inc (INSM) ownership in amended 13G

FMR LLC has filed an amended Schedule 13G, disclosing a beneficial ownership of 7.4% in Insmed Inc (INSM), amounting to 16,127,583.08 shares of common stock. Abigail P. Johnson is also reported with beneficial ownership of the same number of shares, holding sole dispositive power …

Motorola Solutions Posts Upbeat Q2 Earnings, Joins Insmed, Diodes, Parker-Hannifin And Other Big Stocks M

Earnings Flash (INSM) Insmed Incorporated Reports Q2 Revenue $425.5M, vs. FactSet Est of $393.7M

Insmed Incorporated (INSM) reported second-quarter revenue of $425.5 million, surpassing FactSet's estimate of $393.7 million. This financial update indicates a stronger-than-expected performance for the biotechnology company during the quarter. The article also notes other recent financial activities and analyst coverage related to Insmed.

Insmed Reports Second-Quarter 2026 Financial Results and Provides Business Update

Insmed (Nasdaq: INSM) reported strong second-quarter 2026 financial results, with total company revenues of $425.5 million. The company raised its full-year 2026 BRINSUPRI revenue guidance to $1.25 billion to $1.40 billion and increased the peak revenue estimate for its three lead programs (BRINSUPRI, TPIP, …

INSMED Inc Q2 2026: Revenue $425.5M, EPS $(0.06) — 10-Q Summary

INSMED Inc reported strong financial results for Q2 2026, with revenue reaching $425.5M, a significant increase of 296% year-over-year. The company also narrowed its net loss to $(13.2M) and diluted EPS to $(0.06), driven by the successful commercial launch of BRINSUPRI and continued international …

Insmed (INSM) Is Up 30.6% After Steeply Narrowing Losses And Raising 2026 Revenue Guidance – What’s Changed

Insmed (NASDAQ:INSM) Shares Gap Up After Better-Than-Expected Earnings

Insmed (INSM) Reports Q2 Earnings: What Key Metrics Have to Say